Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma

Anticancer Research

Volumn 23, Issue 1 B, 2003, Pages 531-536

  Hedman, Mattias ^a   Arnberg, Henrik ^b   Wernlund, Johan ^c   Riska, Henrik ^d   Brodin, Ola ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c UAS   (Sweden)

^d UAS   (Sweden)

Author keywords

CA125; Hyaluronan; Malignant mesothelioma; TPA

Indexed keywords

CA 125 ANTIGEN; CONTRAST MEDIUM; HYALURONIC ACID; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; MALE; MALIGNANT MESOTHELIOMA; PATIENT MONITORING; PERITONEUM MESOTHELIOMA; PLEURA MESOTHELIOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

CA-125 ANTIGEN; FEMALE; HUMANS; HYALURONIC ACID; MALE; MESOTHELIOMA; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TISSUE POLYPEPTIDE ANTIGEN;

EID: 0037233593     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Stridhar K, Doria R and Raub W: New strategies are needed in diffuse malignant mesothelioma. Cancer 70(12): 2969-2979, 1992.
2. Van Gelder T, Damhuis RAM and Hoogsteden HC: Eur Respiratory J 7: 1035-1038, 1994.
3. Johansson L and Linden CJ: Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas. Chest 109: 109-14, 1996.
4. Moreno de la Santa P and Butchart EG: Therapeutic options in malignant mesothelioma. Current Opinion in Oncology 7: 134-137, 1995.
5. Tiong Ong S and Vogelzang NJ: Chemotherapy in malignant pleural mesothelioma; A review. J of Clin Oncology 4(3): 1007-1017, 1996.
6. Solheim OP, Saeter G, Finnanger AM and Stenwig AE: High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Brit J Cancer 65: 956-960, 1992.
7. Hunt KJ, Longton G and Williams MA: Treatment of malignant mesothelioma with methotrexate and vinblastine. With or without platinum chemotherapy. Chest 109: 1239-42, 1996.
8. Rapellino M, Pecchio F and Baldi S: Clinical utility of tissue polypeptide antigen determination in lung cancer management. Anticancer Res 15: 1065-1070, 1995.
9. Bonfrer JMG, Schouwink JH, Korse CM and Baas P: Cyfra 21-1 and TPA as markers in malignant mesothelioma, Anticancer Res 17: 2971-2974, 1997.
10. Martensson G, Thylen A, Lindqvist U and Hjerpe A: The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 73: 1406-10, 1994.
11. Hillerdal G, Lindqvist U and Engström-Laurent A: Hyaluronan in pleural effusions and in serum. Cancer 67: 2410-2414, 1991.
12. Dahl IM, Solheim OP, Erikstein B and Müller E: A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Cancer 64: 68-73, 1989.
13. Dahl IM and Laurent TC: Concentration of hyaluronan in the serum of untreated cancer patients with special reference to patients with mesothelioma. Cancer 62: 326-330, 1988.
14. Simsek H, Kadayifci A and Okan E: High serum level of CA 125 in malignant peritoneal mesothelioma, letter. Eur J Cancer 31A(1): 129, 1995.
15. Simsek H, Kadayifci A and Okan E: Importance of serum CA 125 levels in malignant peritoneal mesothelioma. Tumour Biol 17: 1-4, 1996.
16. LIA-mat® CA 125 II, Directions for USE, BYK-Sangtec Diagnostica GmbH & Co, KG. AB Boule Diagnostics.
17. LIA-mat® TPA-M Prolifigen®, Instructions for use, AB Sangtec Medical.
18. Pharmacia HA Test, Directions for Use, pharmacia AB, Uppsala, Sweden 1995.
19. Almudevar Barcero E, Garcia-Rostan y Peréz GM, Garcia Bragado F and Jimenez C: Prognostic value of high serum levels of CA 125 in malignant secretory peritoneal mesothelioma affecting young women. A case report with different diagnosis and review of the literature. Histopathology 31: 267-273, 1997.
20. Frebourg T, Lerebours G and Delpech B: Serum hyaluronate in malignant pleural mesothelioma. Cancer 59: 2104-2107, 1987.